Suppr超能文献

肿瘤坏死因子相关凋亡诱导配体在体内的杀瘤活性。

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

作者信息

Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin R G, Rauch C T, Schuh J C, Lynch D H

机构信息

Immunex Corporation, Seattle, Washington 98101, USA.

出版信息

Nat Med. 1999 Feb;5(2):157-63. doi: 10.1038/5517.

Abstract

To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.

摘要

为评估肿瘤坏死因子相关凋亡诱导配体(TRAIL)作为癌症治疗药物的效用,我们构建了人源(hu)和鼠源(mu)TRAIL的亮氨酸拉链(LZ)形式,以促进和稳定三聚体的形成。两者均具有生物活性,在体外以相似的比活性诱导人和鼠靶细胞凋亡。与LZ-huCD95L在体内的暴发性肝毒性相反,给予LZ-huTRAIL或LZ-muTRAIL似乎对小鼠正常组织无毒。最后,用LZ-huTRAIL重复治疗可有效抑制CB.17(SCID)小鼠中对TRAIL敏感的人乳腺腺癌细胞系MDA-231的生长,对接受LZ-huTRAIL治疗的SCID小鼠肿瘤进行组织学检查显示,注射后9 - 12小时内肿瘤出现明显的凋亡坏死区域。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验